Targeting the tumor vasculature through the FSHR antibody was explored in breast cancer treatment for the first time, and the antibody helped GBNs enter breast cancer cells because targeting tumor blood vessels does not require extravasation. The gene discussed is FSHR; the disease is neoplasm.